

Serial No. 10/070,084
 Docket No. PU3517USw
 Reply to Office Action of March 30, 2006


Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claim 1 (canceled)


Claim 2 (previously presented) A compound of formula (I)



wherein X is O; R^1 is C_{6-14} aryl substituted with one or more substituents selected from the group consisting of halogen, $-CF_3$, C_{1-8} alkyl, $-CN$, $-SR^6$, $-S(O)_2R^6$; or heterocycle, optionally substituted with one or more substituents selected from the group consisting of C_{1-8} alkyl, $-CN$, and $C_{6-14}arylC_{1-8}alkyl$; R^6 is C_{1-8} alkyl, optionally substituted with halogen; R^7 is C_{1-8} alkyl optionally substituted with hydroxy, $-NH_2$, or heterocycle; R^8 is hydrogen; R^9 is hydrogen or C_{1-8} alkyl; R^4 is heterocycle, optionally substituted with one or more substituents selected from the group consisting of oxo, halogen, C_{1-8} alkyl, $-OR^{11}$ and $-SR^{10}N(R^{10})_2$, $S(O)_2NR^8R^9$; or $C_{6-14}aryl$ substituted with one or more substituents selected from the group consisting of hydroxy, halogen, $-CF_3$, $C_{1-8}alkyl$, hydroxy $C_{1-8}alkyl$, $-CN$, $-NO_2$, $-C(O)NH_2$, $-S(O)R^7$, $-S(O)_2R^7$, $-S(O)_2NR^8R^9$, $-OR^{11}$, $-C(O)NR^{11}$, $-C(O)OR^{11}$, $-NR^{11}$, $-NC(O)R^{11}$, and heterocycle which may be optionally substituted with one or more substituents selected from the group consisting of oxo, $C_{1-8}alkyl$ and heterocycle $C_{1-8}alkyl$; R^8 and R^9 are the same or different and are selected from the group consisting of hydrogen, $C_{1-8}alkyl$, $C_{1-8}alkylheterocycle$, heterocycle, and $C_{3-6}cycloalkyl$; R^{10} is $C_{1-8}alkyl$; R^{11} is $C_{1-8}alkyl$, optionally substituted with $-SO_2NR^8R^9$; and R^5 is halogen or $-NO_2$; or a pharmaceutically acceptable salt thereof.


Claim 3 (previously presented) A compound of formula (I)

Serial No. 10/070,084
 Docket No. PU3517USw
 Reply to Office Action of March 30, 2006



wherein X is O; R^1 is C_{6-14} aryl substituted with one or more substituents selected from the group consisting of halogen, $-CF_3$, C_{1-8} alkyl, and $-CN$; R^2 and R^3 are hydrogen; R^4 is C_{6-14} aryl substituted with one or more substituents selected from the group consisting of halogen, C_{1-8} alkyl, $-CN$, $-NO_2$, $-S(O)R^7$, $-S(O)_2R^7$, $-NS(O)_2R^7$, wherein R^7 is $-NH_2$; and R^5 is halogen; or a pharmaceutically acceptable salt thereof.

Claim 4 (previously presented) A compound of formula (I)




wherein X is O; R^1 is C_{6-14} aryl which may be optionally substituted with one or more substituents selected from the group consisting of halogen, C_{1-8} alkyl, CF_3 , $-CN$; R^2 and R^3 are hydrogen; R^4 is C_{6-14} aryl substituted with one or more substituents selected from the group consisting of C_{1-8} alkyl and $S(O)_2NR^8R^9$, wherein R^8 and R^9 are independently selected from the group consisting of hydrogen, C_{3-6} cycloalkyl, C_{1-8} alkyl optionally substituted with one or more substituents selected from the group consisting of oxo, heterocycle, CN and C_{6-14} aryl optionally substituted with alkoxy, C_{1-8} alkylamino, C_{1-8} alkylheterocycle, heterocycle, heterocycle C_{1-8} alkyl, C_{3-6} cycloalkyl C_{1-8} alkyl, and C_{3-6} cycloalkyl; R^5 is hydrogen, halogen, C_{1-}

Serial No. 10/070,084
 Docket No. P13517USw
 Reply to Office Action of March 30, 2006


alkyl, -NO₂, -NH₂, C₁₋₈alkylamino, CF₃, or alkoxy; or a pharmaceutically acceptable salt thereof.

Claim 5 (previously presented) A compound of formula (I)



wherein X is O, R¹ is C₆₋₁₄aryl substituted with one or more substituents selected from the group consisting of halogen, -CF₃, C₁₋₈alkyl, and -CN; R² and R³ are hydrogen; R⁴ is C₆₋₁₄aryl substituted with one or more substituents selected from the group consisting of halogen, C₁₋₈alkyl, -CN, -NO₂, -S(O)R⁷, -S(O)₂R⁷, -NS(O)₂R⁷, wherein R⁷ is -NH₂; and R⁵ is halogen; or a pharmaceutically acceptable salt thereof.

Claim 6 (currently amended) A compound of formula (IA)



wherein:

X is C, O, or N;

Serial No. 10/070,084
 Pocket No. PU3517USw
 Reply to Office Action of March 30, 2006

R^1 is C_{6-14} aryl which may be optionally substituted with one or more substituents selected from the group consisting of halogen, $-CF_3$, C_{1-8} alkyl, C_{1-8} alkylamino, alkoxy, C_{3-6} cycloalkyl, C_{2-6} alkenyl, C_{6-14} aryl C_{2-6} alkenyl, $-CN$, $-NO_2$, $-NH_2$, $-SR^6$, $-S(O)_2R^6$, $-S(O)R^7$, $-S(O)_2R^7$, $-C(O)R^7$, C_{2-6} alkenyl which may be optionally substituted with a substituent selected from the group consisting of hydroxy, halogen, aryl, and heterocycle and C_{2-6} alkynyl which may be optionally substituted with a substituent selected from the group consisting of hydroxy, halogen, aryl, C_{3-6} cycloalkyl, and heterocycle;

R^6 is C_{1-8} alkyl optionally substituted with one or more substituents selected from the group consisting of hydroxyl, halogen, $-CF_3$, aryl, and heterocycle;

R^7 is C_{1-8} alkyl, optionally substituted with one or more substituents selected from the group consisting of hydroxy, halogen, aryl, C_{3-6} cycloalkyl and heterocycle; $-NH_2$; or heterocycle;

R^2 is hydrogen, halogen, or C_{1-8} alkyl;

R^3 is hydrogen;

R^4 is C_{6-14} aryl substituted with one or more substituents selected from the group consisting of hydroxy, halogen, $-CF_3$, C_{1-8} alkyl, hydroxy C_{1-8} alkyl, $-CN$, $-NO_2$, C_{1-8} alkylamino, heterocycle C_{1-8} alkyl, $-C(O)NH_2$, $-S(O)R^7$, $-S(O)_2R^7$, $-C(O)R^7$, $-NS(O)_2R^7$, $-S(O)_2NR^8R^9$, $-S(O)_2NHR^{11}$, $-S(O)_2R^{11}$, $-S(O)_2NR^7COR^{11}$, $-S(O)_2NHCOR^{11}$, $-S(O)_2[COR^{11}]_n$ wherein n is 1, 2, or 3, $-OR^{11}$, $-OR^{11}OR^{11}$, $-C(O)R^{11}$, $-C(O)NR^{11}$, $-C(O)OR^{11}$, $-NR^{11}$, $-NC(O)R^{11}$, heterocycle C_{2-6} alkenyl, heterocycle which may be optionally substituted with one or more substituents selected from the group consisting of oxo, C_{1-8} alkyl, and $C(O)OR^{11}$, and C_{1-8} alkyl which may be optionally substituted with one or more substituents selected from the group consisting of $-CN$ and heterocycle, optionally substituted with $-C(O)R^{11}$;

R^8 and R^9 are independently selected from the group consisting of hydrogen, C_{3-6} cycloalkyl, C_{1-8} alkyl optionally substituted with one or more substituents selected from the group consisting of oxo, heterocycle, CN and C_{6-14} aryl optionally substituted with alkoxy, C_{1-8} alkylamino, C_{1-8} alkylheterocycle, heterocycle, heterocycle C_{1-8} alkyl, C_{3-6} cycloalkyl C_{1-8} alkyl, and C_{3-6} cycloalkyl;

R^{11} is C_{1-8} alkyl, optionally substituted with one or more substituents selected from the group consisting of hydrogen, hydroxy, halogen, C_{1-8} alkyl, C_{3-6} cycloalkyl, alkoxy, $-S(O)_2NR^8R^9$, $NCONH_2$, and heterocycle optionally substituted with one or more substituents selected from the group consisting of oxo, hydroxy, and C_{1-8} alkyl;

Serial No. 10/070,084
 Docket No. PU3517USw
 Reply to Office Action of March 30, 2006

heterocycle optionally substituted with heterocycleC₁₋₈alkyl; or C₆₋₁₄aryl optionally substituted with alkoxy;

R⁵ is hydrogen, halogen, C₁₋₈alkyl, -NO₂, -NH₂, C₁₋₈alkylamino, CF₃, or alkoxy;
 or a pharmaceutically acceptable salt thereof ~~provided that~~


~~a) when X is C; R² is hydrogen, halogen or C₁₋₈alkyl; R³ is hydrogen; R⁴ is C₆₋₁₄aryl substituted with halogen, hydroxy, or C₁₋₈alkyl; R⁵ is hydrogen, halogen, C₁₋₈alkyl, or alkoxy; then R¹ cannot be C₁₋₈alkyl, C₂₋₆cycloalkyl, or C₆₋₁₄aryl substituted with halogen, C₁₋₈alkyl, or C₆₋₁₄arylC₂₋₆alkenyl; and~~

~~(b) when X is C; R² is hydrogen or alkyl; R³ is hydrogen; R⁴ is C₆₋₁₄aryl substituted with halogen, CN, alkyl, or -NO₂; R⁵ is hydrogen, -NO₂, or -NH₂; then R¹ cannot be C₁₀₋₁₄aryl substituted with alkoxy.~~

Claim 7 (previously presented) A compound of formula (IA) according to claim 6 wherein X is O; R¹ is C₆₋₁₄aryl substituted with one or more substituents selected from the group consisting of halogen, -CF₃, C₁₋₈alkyl, -CN, C₂₋₆alkenyl which may be optionally substituted with a substituent selected from the group consisting of hydroxy, halogen, aryl, and heterocycle and C₂₋₆alkynyl which may be optionally substituted with a substituent selected from the group consisting of hydroxy, halogen, aryl, C₃₋₆cycloalkyl, and heterocycle; R² and R³ are hydrogen; R⁴ is C₆₋₁₄aryl substituted with one or more substituents selected from the group consisting of C₁₋₈alkyl, -S(O)₂R⁷, -S(O)₂NR⁸R⁹, -OR¹¹, heterocycleC₂₋₆alkenyl, and heterocycle which may be optionally substituted with oxo; and R⁵ is halogen; or a pharmaceutically acceptable salt thereof.

Claim 8 (canceled)


Claim 9 (previously presented) A compound of formula (IB)



Serial No. 10/070,084
 Docket No. PU3517USw
 Reply to Office Action of March 30, 2006

wherein X is O; R¹ is C₆₋₁₄aryl substituted with one or more substituents selected from the group consisting of halogen, -CF₃, and -CN; R² is hydrogen; R³ is hydrogen; R⁴ is heterocycle; and R⁵ is halogen; or a pharmaceutically acceptable salt thereof.

Claim 10 (currently amended) A compound of formula (IC)



wherein:

X is C, O, or N;

R¹ is heterocycle, optionally substituted with one or more substituents selected from the group consisting of C₁₋₈alkyl, halogen, -CN, C₆₋₁₄arylC₁₋₈alkyl and heterocycle;

R² is hydrogen, halogen, or C₁₋₈alkyl;

R³ is hydrogen;

R⁴ is C₆₋₁₄aryl substituted with one or more substituents selected from the group consisting of hydroxy, halogen, -CF₃, C₁₋₈alkyl, hydroxyC₁₋₈alkyl, -CN, -NO₂, C₁₋₈alkylamino, heterocycleC₁₋₈alkyl, -C(O)NH₂, -S(O)R⁷, -S(O)₂R⁷, -C(O)R⁷, -NS(O)₂R⁷, -S(O)₂NR⁸R⁹, -S(O)₂NHR¹¹, -S(O)₂R¹¹, -S(O)₂NR⁷COR¹¹, -S(O)₂NHCOR¹¹, -S(O)₂[COR¹¹]_n wherein n is 1, 2, or 3, -OR¹¹, -OR¹¹OR¹¹, -C(O)R¹¹, -C(O)NR¹¹, -C(O)OR¹¹, -NR¹¹, -NC(O)R¹¹, heterocycleC₂₋₆alkenyl, heterocycle which may be optionally substituted with one or more substituents selected from the group consisting of oxo, C₁₋₈alkyl, and C(O)OR¹¹, and C₁₋₈alkyl which may be optionally substituted with one or more substituents selected from the group consisting of -CN and heterocycle, optionally substituted with -C(O)R¹¹;

Serial No. 10/070,084
 Docket No. PU3517USw
 Reply to Office Action of March 30, 2006

R^7 is C_{1-8} alkyl, optionally substituted with one or more substituents selected from the group consisting of hydroxy, halogen, aryl, C_{3-6} cycloalkyl and heterocycle; $-NH_2$; or heterocycle;

R^8 and R^9 are independently selected from the group consisting of hydrogen, C_{3-6} cycloalkyl, C_{1-8} alkyl optionally substituted with one or more substituents selected from the group consisting of oxo, heterocycle, CN and C_{6-14} aryl optionally substituted with alkoxy, C_{1-8} alkylamino, C_{1-8} alkylheterocycle, heterocycle, heterocycle C_{1-8} alkyl, C_{3-6} cycloalkyl C_{1-8} alkyl, and C_{3-6} cycloalkyl;


R^{11} is C_{1-8} alkyl, optionally substituted with one or more substituents selected from the group consisting of hydrogen, C_{1-8} alkyl, alkoxy, $-S(O)_2NR^8R^9$, $-NR^8R^9$, and heterocycle, optionally substituted with one or more substituents selected from the group consisting of oxo and C_{1-8} alkyl;

R^5 is hydrogen, halogen, C_{1-8} alkyl, $-NO_2$, $-NH_2$, C_{1-8} alkylamino, CF_3 , or alkoxy; or a pharmaceutically acceptable salt thereof.

Claim 11 (previously presented) A compound of formula (IC) according to claim 10 wherein X is O; R^1 is heterocycle, optionally substituted with $-CN$; R^2 and R^3 are hydrogen; R^4 is C_{6-14} aryl substituted with one or more substituents selected from the group consisting of C_{1-8} alkyl, $-S(O)_2NR^8R^9$, $-OR^{11}$, and heterocycle which may be optionally substituted with one or more substituents selected from the group consisting of oxo; and R^5 is halogen; or a pharmaceutically acceptable salt thereof.

Claim 12 (canceled)

Claim 13 (currently amended) A compound of formula (ID) ~~according to claim 12~~



wherein X is O; R^1 is heterocycle; R^2 and R^3 are hydrogen; R^4 is heterocycle; and R^5 is halogen; or a pharmaceutically acceptable salt thereof.

Serial No. 10/070,084
Docket No. PU3517USw
Reply to Office Action of March 30, 2006


Claim 14 (canceled)

Claim 15 (canceled)

Claim 16 (canceled)

Claim 17 (canceled)

Claim 18 (previously presented) A compound of formula (III)




wherein R¹ is C₆₋₁₄aryl substituted with one or more substituents selected from the group consisting of halogen, -CF₃, C₁₋₈alkyl, -CN, -SR⁶, -S(O)₂R⁶, or heterocycle, optionally substituted with one or more substituents selected from the group consisting of C₁₋₈alkyl, -CN, and C₆₋₁₄arylC₁₋₈alkyl; R⁶ is C₁₋₈alkyl, optionally substituted with halogen; R⁷ is C₁₋₈alkyl, optionally substituted with hydroxy; -NH₂; or heterocycle; R⁴ is heterocycle, optionally substituted with one or more substituents selected from the group consisting of oxo, halogen, C₁₋₈alkyl, -OR¹¹ and -SR¹⁰N(R¹⁰)₂; or C₆₋₁₄aryl substituted with one or more substituents selected from the group consisting of hydroxy, -CF₃, C₁₋₈alkyl, hydroxyC₁₋₈alkyl, -CN, -NO₂, -C(O)NH₂, -S(O)₂R⁷, -S(O)₂NR⁸R⁹, -OR¹¹, -C(O)NR¹¹, -C(O)OR¹¹, -NR¹¹, -NC(O)R¹¹, heterocycle which may be optionally substituted with one or more substituents selected from the group consisting of oxo and C₁₋₈alkyl; R⁸ and R⁹ are the same or different and are selected from the group consisting of hydrogen, C₁₋₈alkyl, C₁₋₈alkylheterocycle, heterocycle, and C₃₋₆cycloalkyl; R¹⁰ is C₁₋₈alkyl; R¹¹ is C₁₋₈alkyl, optionally substituted with -S(O)₂NR⁸R⁹; and R⁵ is halogen or -NO₂; or a pharmaceutically acceptable salt thereof.

Serial No. 10/070,084
 Docket No. P1J3517USw
 Reply to Office Action of March 30, 2006

Claim 19 (previously presented) A compound of formula (III) according to claim 18 wherein R^1 is C_{6-14} aryl substituted with one or more substituents selected from the group consisting of halogen, $-CF_3$, C_{1-8} alkyl, and $-CN$; R^4 is C_{6-14} aryl substituted with one or more substituents selected from the group consisting of halogen, C_{1-8} alkyl, $-CN$, $-NO_2$, $-S(O)R^7$, $-S(O)_2R^7$, $-NS(O)_2R^7$, wherein R^7 is $-NH_2$; and R^5 is halogen; or a pharmaceutically acceptable salt thereof.

Claim 20 (previously presented) A compound of formula (I)



wherein:

X is O;

R^1 is phenyl which is substituted in the *meta* position with one or more substituents selected from the group consisting of halogen, $-CF_3$, C_{1-8} alkyl, C_{1-8} alkylamino, alkoxy, C_{3-6} cycloalkyl, C_{2-6} alkenyl, C_{6-14} aryl, C_{2-6} alkenyl, $-CN$, $-NO_2$, $-NH_2$, $-SR^6$, $-S(O)_2R^6$, $-S(O)R^7$, $-S(O)_2R^7$, $-C(O)R^7$, C_{2-6} alkenyl which may be optionally substituted with a substituent selected from the group consisting of hydroxy, halogen, aryl, and heterocycle, and C_{2-6} alkynyl which may be optionally substituted with a substituent selected from the group consisting of hydroxy, halogen, aryl, C_{3-6} cycloalkyl, and heterocycle;

R^2 is hydrogen;

R^3 is hydrogen;

R^4 is phenyl substituted in the *ortho* position with a substituent selected from the group consisting of hydroxy, halogen, $-CF_3$, or C_{1-8} alkyl and substituted at the *para* position with a substituent selected from the group consisting of hydroxy, halogen, $-CF_3$, C_{1-8} alkyl, hydroxy C_{1-8} alkyl, $-CN$, $-NO_2$, C_{1-8} alkylamino, heterocycle C_{1-8} alkyl, $-C(O)NH_2$, $-S(O)R^7$, $-S(O)_2R^7$, $-C(O)R^7$, $-NS(O)_2R^7$, $-S(O)_2NHR^8$, $-S(O)_2NHR^{11}$, $-SO_2R^{11}$, $-OR^{11}$, $-C(O)R^{11}$, $-C(O)NR^{11}$, $-C(O)OR^{11}$, $-NR^{11}$, $-NC(O)R^{11}$, heterocycle C_{2-6} alkenyl, heterocycle which may be optionally substituted with one or more substituents selected from the group

Serial No. 10/070,084
Docket No. PUJ3517USW
Reply to Office Action of March 30, 2006

consisting of oxo, C₁₋₈alkyl, and C(O)OR¹¹, and C₁₋₈alkyl which may be optionally substituted with one or more substituents selected from the group consisting of -CN and heterocycle, optionally substituted with -C(O)R¹¹;

R⁵ is a substituent in the *para* position relative to X and is selected from the group consisting of halogen, C₁₋₈alkyl, -NO₂, -NH₂, C₁₋₈alkylamino, CF₃, or alkoxy;

R⁶ is C₁₋₈alkyl, optionally substituted with one or more substituents selected from the group consisting of hydroxy, halogen, -CF₃, aryl, and heterocycle;

R⁷ is C₁₋₈alkyl, optionally substituted with one or more substituents selected from the group consisting of hydroxy, halogen, aryl, C₃₋₆cycloalkyl and heterocycle; -NH₂; or heterocycle;

R⁸ and R⁹ are independently selected from the group consisting of hydrogen; C₃₋₆cycloalkyl; C₁₋₈alkyl optionally substituted with one or more substituents selected from the group consisting of oxo, heterocycle, CN and C₆₋₁₄aryl optionally substituted with alkoxy, C₁₋₈alkylamino, C₁₋₈alkylheterocycle, heterocycle, heterocycleC₁₋₈alkyl, C₃₋₆cycloalkylC₁₋₈alkyl, and C₃₋₆cycloalkyl; or -C(O)NH₂;

R¹¹ is C₁₋₈alkyl, optionally substituted with one or more substituents selected from the group consisting of hydrogen, C₁₋₈alkyl, -S(O)₂NR⁸R⁹, -NR⁸R⁹, and heterocycle, optionally substituted with one or more substituents selected from the group consisting of oxo and C₁₋₈alkyl; or a pharmaceutically acceptable salt thereof.

Claim 21 (canceled)

Claim 22 (canceled)

Claim 23 (previously presented) A compound selected from the group consisting of:

2-[2-(1-benzothiophen-2-ylcarbonyl)-4-chlorophenoxy]-N-phenylacetamide;

2-(2-benzoyl-4-chlorophenoxy)-N-[4-(1H-imidazol-1-yl)phenyl]acetamide;

2-[4-chloro-2-(2-thienylcarbonyl)phenoxy]-N-[2-methyl-4-(1-oxo-1λ⁴-4,4-thiazinan-4-yl)phenyl]acetamide;

2-(2-benzoyl-4-chlorophenoxy)-N-[4-(1H-1,2,4-triazol-1-yl)phenyl]acetamide;

2-(2-benzoyl-4-chlorophenoxy)-N-[4-(4-morpholinyl)phenyl]acetamide;

N-[4-(aminosulfonyl)phenyl]-2-(2-benzoyl-4-chlorophenoxy)acetamide;

2-(2-benzoyl-4-chlorophenoxy)-N-{4-[(1,3-thiazol-2-ylamino)sulfonyl]phenyl}acetamide;

Serial No. 10/070,084
Docket No. PU3517USw
Reply to Office Action of March 30, 2006

2-(2-benzoyl-4-chlorophenoxy)-N-[4-(4-methyl-1-piperazinyl)phenyl]acetamide;
2-(2-benzoyl-4-chlorophenoxy)-N-[4-(hydroxymethyl)phenyl]acetamide;
2-(2-benzoyl-4-chlorophenoxy)-N-{4-[(methylamino)sulfonyl]phenyl}acetamide;
2-(2-benzoyl-4-chlorophenoxy)-N-[4-(1-oxo-1lambda-4~,4-thiazinan-4-yl)phenyl]acetamide;
2-(2-benzoyl-4-chlorophenoxy)-N-[4-(1,1-dioxo-1lambda-6~,4-thiazinan-4-yl)phenyl]acetamide;
2-(2-benzoyl-4-chlorophenoxy)-N-[2-methyl-4-(4-morpholinyl)phenyl]acetamide;
2-(2-benzoyl-4-chlorophenoxy)-N-{4-[3-(dimethylamino)propoxy]-2-methylphenyl}acetamide;
2-(2-benzoyl-4-chlorophenoxy)-N-[4-(1-hydroxyethyl)phenyl]acetamide;
2-(2-benzoyl-4-chlorophenoxy)-N-[4-(1-hydroxyethyl)phenyl]acetamide;
2-(2-benzoyl-4-chlorophenoxy)-N-[2-methyl-4-(1-oxo-1lambda-4~,4-thiazinan-4-yl)phenyl]acetamide;
2-(2-benzoyl-4-chlorophenoxy)-N-{2-methyl-4-[3-(1-pyrrolidinyl)propoxy]phenyl}acetamide;
2-(2-benzoyl-4-chlorophenoxy)-N-(1H-indazol-5-yl)acetamide;
2-(2-benzoyl-4-chlorophenoxy)-N-{2-methyl-4-[3-(4-morpholinyl)propoxy]phenyl}acetamide;
2-(2-benzoyl-4-chlorophenoxy)-N-{4-[3-(1H-imidazol-1-yl)propoxy]-2-methylphenyl}acetamide;
2-(2-benzoyl-4-chlorophenoxy)-N-(1H-indazol-6-yl)acetamide;
2-[4-chloro-2-(2-thienylcarbonyl)phenoxy]-N-(1H-indazol-5-yl)acetamide;
2-[4-chloro-2-(2-furoyl)phenoxy]-N-(1H-indazol-5-yl)acetamide;
2-[4-chloro-2-(3-thienylcarbonyl)phenoxy]-N-(1H-indazol-5-yl)acetamide;
2-[4-chloro-2-(2-thienylcarbonyl)phenoxy]-N-{2-methyl-4-[3-(4-morpholinyl)propoxy]phenyl}acetamide;
2-[4-chloro-2-(2-thienylcarbonyl)phenoxy]-N-[4-(1-oxo-1lambda-4~,4-thiazinan-4-yl)phenyl]acetamide;

Serial No. 10/070,084
Docket No. P113517USw
Reply to Office Action of March 30, 2006

2-(2-benzoyl-4-chlorophenoxy)-N-{2-methyl-4-[3-(1-oxo-1lambda~4~,4-thiazinan-4-yl)propoxy]phenyl}acetamide;

2-[4-chloro-2-(2-furoyl)phenoxy]-N-[2-methyl-4-(1-oxo-1lambda~4~,4-thiazinan-4-yl)phenyl]acetamide;

N-[4-(aminosulfonyl)-2-methylphenyl]-2-(2-benzoyl-4-chlorophenoxy)acetamide;

N-[4-(aminosulfonyl)-2-methylphenyl]-2-[4-chloro-2-(2-thienylcarbonyl)phenoxy]acetamide;

2-[2-(1-benzofuran-2-ylcarbonyl)-4-chlorophenoxy]-N-phenylacetamide

2-[4-chloro-2-(1,3-thiazol-2-ylcarbonyl)phenoxy]-N-phenylacetamide;

N-[4-(aminosulfonyl)-2-methylphenyl]-2-[4-chloro-2-(2-furoyl)phenoxy]acetamide;

2-[4-chloro-2-(2-furoyl)phenoxy]-N-(1H-indazol-6-yl)acetamide;

2-[4-chloro-2-(3-furoyl)phenoxy]-N-[2-methyl-4-(1-oxo-1lambda~4~,4-thiazinan-4-yl)phenyl]acetamide;

2-[4-chloro-2-(3-thienylcarbonyl)phenoxy]-N-[4-(1-oxo-1lambda~4~,4-thiazinan-4-yl)phenyl]acetamide;

2-[4-chloro-2-(3-thienylcarbonyl)phenoxy]-N-[2-methyl-4-(1-oxo-1lambda~4~,4-thiazinan-4-yl)phenyl]acetamide;

2-[4-chloro-2-[(1-methyl-1H-pyrrol-2-yl)carbonyl]phenoxy]-N-phenylacetamide;

2-[4-chloro-2-[[5-(2-pyridinyl)-2-thienyl]carbonyl]phenoxy]-N-phenylacetamide;

2-[4-chloro-2-(1,3-thiazol-2-ylcarbonyl)phenoxy]-N-(1H-indazol-5-yl)acetamide;

2-[4-chloro-2-(1,3-thiazol-2-ylcarbonyl)phenoxy]-N-[2-methyl-4-(1-oxo-1lambda~4~,4-thiazinan-4-yl)phenyl]acetamide;

2-[4-chloro-2-(3-cyanobenzoyl)phenoxy]-N-[2-methyl-4-(1-oxo-1lambda~4~,4-thiazinan-4-yl)phenyl]acetamide;

2-[4-chloro-2-(3-pyridinylcarbonyl)phenoxy]-N-[2-methyl-4-(1-oxo-1lambda~4~,4-thiazinan-4-yl)phenyl]acetamide;

2-[2-(2-bromobenzoyl)-4-chlorophenoxy]-N-[2-methyl-4-(1-oxo-1lambda~4~,4-thiazinan-4-yl)phenyl]acetamide;

2-[2-(4-bromobenzoyl)-4-chlorophenoxy]-N-[2-methyl-4-(1-oxo-1lambda~4~,4-thiazinan-4-yl)phenyl]acetamide;

N-[4-(aminosulfonyl)-2-methylphenyl]-2-[2-(2-bromobenzoyl)-4-chlorophenoxy]acetamide;

Serial No. 10/070,084
Docket No. PU35171/Sw
Reply to Office Action of March 30, 2006

2-{4-chloro-2-[(5-methyl-3-isoxazolyl)carbonyl]phenoxy}-N-[2-methyl-4-(1-oxo-1lambda~4~,4-thiazinan-4-yl)phenyl]acetamide;

2-[4-chloro-2-(3-fluorobenzoyl)phenoxy]-N-[2-methyl-4-(1-oxo-1lambda~4~,4-thiazinan-4-yl)phenyl]acetamide;

2-[4-chloro-2-(3-chlorobenzoyl)phenoxy]-N-[2-methyl-4-(1-oxo-1lambda~4~,4-thiazinan-4-yl)phenyl]acetamide;

N-[4-(aminosulfonyl)-2-methylphenyl]-2-[4-chloro-2-(3-cyanobenzoyl)phenoxy]acetamide;

N-[4-(aminosulfonyl)-2-methylphenyl]-2-[4-chloro-2-(3-fluorobenzoyl)phenoxy]acetamide;

N-[4-(aminosulfonyl)-2-methylphenyl]-2-[4-chloro-2-(3-chlorobenzoyl)phenoxy]acetamide;

2-{4-chloro-2-[(4-cyano-2-thienyl)carbonyl]phenoxy}-N-[2-methyl-4-(1-oxo-1lambda~4~,4-thiazinan-4-yl)phenyl]acetamide;

N-[4-(aminosulfonyl)-2-methylphenyl]-2-{4-chloro-2-[(4-cyano-2-thienyl)carbonyl]phenoxy}acetamide;

2-{4-chloro-2-[3-(trifluoromethyl)benzoyl]phenoxy}-N-[2-methyl-4-(1-oxo-1lambda~4~,4-thiazinan-4-yl)phenyl]acetamide;

2-[2-(3-bromobenzoyl)-4-chlorophenoxy]-N-[2-methyl-4-(1-oxo-1lambda~4~,4-thiazinan-4-yl)phenyl]acetamide;

2-[4-chloro-2-(3,5-difluorobenzoyl)phenoxy]-N-[2-methyl-4-(1-oxo-1lambda~4~,4-thiazinan-4-yl)phenyl]acetamide;

N-[4-(aminosulfonyl)-2-methylphenyl]-2-[2-(3-bromobenzoyl)-4-chlorophenoxy]acetamide;

2-[4-chloro-2-(3-methylbenzoyl)phenoxy]-N-[2-methyl-4-(1-oxo-1lambda~4~,4-thiazinan-4-yl)phenyl]acetamide;

2-[4-chloro-2-(3-cyanobenzoyl)phenoxy]-N-(5-methyl-1H-indazol-6-yl)acetamide;

N-[4-(aminosulfonyl)-2-methylphenyl]-2-[4-chloro-2-(3-pyridinylcarbonyl)phenoxy]acetamide;

2-[4-chloro-2-(3-cyanobenzoyl)phenoxy]-N-{2-methyl-4-[3-(1-pyrrolidinyl)propoxy]phenyl}acetamide;

N-[4-(aminosulfonyl)-2-methylphenyl]-2-{4-chloro-2-[(1-methyl-1H-imidazol-2-yl)carbonyl]phenoxy}acetamide;

N-[4-(aminosulfonyl)-2-methylphenyl]-2-[4-chloro-2-(1,3-thiazol-2-ylcarbonyl)phenyl]acetamide;

Serial No. 10/070,084
Docket No. PU3517USw
Reply to Office Action of March 30, 2006

2-[4-chloro-2-(3,5-difluorobenzoyl)phenoxy]-N-{2-methyl-4-[3-(1-pyrrolidinyl)propoxy]phenyl}acetamide;

N-[4-(aminosulfonyl)-2-methylphenyl]-2-[4-chloro-2-(3,5-difluorobenzoyl)phenoxy]acetamide;

2-{4-chloro-2-[3-fluoro-5-(trifluoromethyl)benzoyl]phenoxy}-N-[2-methyl-4-(1-oxo-1 lambda~4~,4-thiazinan-4-yl)phenyl]acetamide

N-(1,3-benzothiazol-6-yl)-2-(2-benzoyl-4-chlorophenoxy)acetamide

2-(4-chloro-2-{3-[(trifluoromethyl)sulfonyl]benzoyl}phenoxy)-N-[2-methyl-4-(1-oxo-1 lambda~4~,4-thiazinan-4-yl)phenyl]acetamide

2-[4-chloro-2-(3-ethynylbenzoyl)phenoxy]-N-[2-methyl-4-(1-oxo-1 lambda~4~,4-thiazinan-4-yl)phenyl]acetamide;

2-[4-chloro-2-(3,5-dichlorobenzoyl)phenoxy]-N-[2-methyl-4-(1-oxo-1 lambda~4~,4-thiazinan-4-yl)phenyl]acetamide;

N-[4-(aminosulfonyl)-2-methylphenyl]-2-[4-chloro-2-(3,5-dichlorobenzoyl)phenoxy]acetamide;

N-[4-(aminosulfonyl)-2-methylphenyl]-2-{4-chloro-2-[3-fluoro-5-(trifluoromethyl)benzoyl]phenoxy}acetamide;

N-(1,3-benzothiazol-6-yl)-2-[4-chloro-2-(3,5-difluorobenzoyl)phenoxy]acetamide

2-[4-chloro-2-(3-cyanobenzoyl)phenoxy]-N-(2-methyl-1,3-benzothiazol-5-yl)acetamide

N-[4-(aminosulfonyl)-2-methylphenyl]-2-(4-chloro-2-{3-[(trifluoromethyl)sulfonyl]benzoyl}phenoxy)acetamide;

N-[4-(aminosulfonyl)-2-methylphenyl]-2-[4-chloro-2-(3-ethynylbenzoyl)phenoxy]acetamide;

2-(2-benzoyl-4-chlorophenoxy)-N-[4-(methylsulfonyl)phenyl]acetamide;

N-[4-(aminosulfonyl)-2-methylphenyl]-2-{4-chloro-2-[3-(2-cyclopentylethynyl)benzoyl]phenoxy}acetamide;

2-{4-chloro-2-[3-fluoro-5-(trifluoromethyl)benzoyl]phenoxy}-N-(5-methyl-1H-indazol-6-yl)acetamide;

2-[4-chloro-2-(3,5-dichlorobenzoyl)phenoxy]-N-(5-methyl-1H-indazol-6-yl)acetamide;

N-[4-(aminosulfonyl)-2-methylphenyl]-2-{4-chloro-2-[3-(2-phenylethynyl)benzoyl]phenoxy}acetamide;

2-[4-chloro-2-(3,5-difluorobenzoyl)phenoxy]-N-(5-methyl-1H-indazol-6-yl)acetamide;

Serial No. 10/070,084
Docket No. PU3517USw
Reply to Office Action of March 30, 2006

2-[4-chloro-2-(3,5-difluorobenzoyl)phenoxy]-N-[2-methyl-4-(methylsulfonyl)phenyl]acetamide;

N-(1,2-benzisothiazol-5-yl)-2-[4-chloro-2-(3-cyanobenzoyl)phenoxy]acetamide;

2-[4-chloro-2-(3,5-dichlorobenzoyl)phenoxy]-N-(5-methyl-1H-benzimidazol-6-yl)acetamide;

2-[4-chloro-2-(3,5-difluorobenzoyl)phenoxy]-N-(5-methyl-1H-benzimidazol-6-yl)acetamide;

2-{4-chloro-2-[3-fluoro-5-(trifluoromethyl)benzoyl]phenoxy}-N-(5-methyl-1H-benzimidazol-6-yl)acetamide

2-[4-chloro-2-(3,5-difluorobenzoyl)phenoxy]-1-(2,3-dihydro-1H-indol-1-yl)-1-ethanone;

2-[4-chloro-2-(3-cyanobenzoyl)phenoxy]-N-[2-methyl-4-(methylsulfonyl)phenyl]acetamide;

2-[4-chloro-2-(3-ethynylbenzoyl)phenoxy]-N-[2-methyl-4-(methylsulfonyl)phenyl]acetamide;

N-{4-[3-(aminosulfonyl)propoxy]-2-methylphenyl}-2-[4-chloro-2-(3,5-difluorobenzoyl)phenoxy]acetamide;

2-{2-[3,5-bis(trifluoromethyl)benzoyl]-4-chlorophenoxy}-N-(5-methyl-1H-benzimidazol-6-yl)acetamide;

2-{2-[(5-bromo-3-pyridinyl)carbonyl]-4-chlorophenoxy}-N-(5-methyl-1H-benzimidazol-6-yl)acetamide;

2-{4-chloro-2-[3-fluoro-5-(trifluoromethyl)benzoyl]phenoxy}-N-(6-methyl-1,3-benzothiazol-5-yl)acetamide;

N-{4-[3-(aminosulfonyl)propoxy]-2-methylphenyl}-2-{4-chloro-2-[3-fluoro-5-(trifluoromethyl)benzoyl]phenoxy}acetamide;

N-[4-(aminosulfonyl)-2-methylphenyl]-2-(4-chloro-2-{3-[(trifluoromethyl)sulfonyl]benzoyl}phenoxy)acetamide;

2-[4-chloro-2-(3,5-difluorobenzoyl)phenoxy]-N-[4-(1,3-thiazol-2-yl)phenyl]acetamide

2-[4-chloro-2-(3,5-difluorobenzoyl)phenoxy]-N-[4-(1,3-oxazol-2-yl)phenyl]acetamide

2-[4-chloro-2-(3,5-difluorobenzoyl)phenoxy]-N-{4-[(3-hydroxypropyl)sulfonyl]-2-methylphenyl}acetamide;

2-{4-chloro-2-[3-fluoro-5-(trifluoromethyl)benzoyl]phenoxy}-N-(2-methyl-4-{3-[(methylamino)sulfonyl]propoxy}phenyl)acetamide;

2-{4-chloro-2-[3-fluoro-5-(trifluoromethyl)benzoyl]phenoxy}-N-(4-{3-[(dimethylamino)sulfonyl]propoxy}-2-methylphenyl)acetamide;

Serial No. 10/070,084
Docket No. PU3517USW
Reply to Office Action of March 30, 2006

N-[4-(aminosulfonyl)-2-methylphenyl]-2-{2-[(5-bromo-3-pyridinyl)carbonyl]-4-chlorophenoxy}acetamide;

2-{4-chloro-2-[3-fluoro-5-(trifluoromethyl)benzoyl]phenoxy}-*N*-{4-[3-(1*H*-imidazol-1-yl)propoxy]-2-methylphenyl}acetamide;

2-{4-chloro-2-[3-fluoro-5-(trifluoromethyl)benzoyl]phenoxy}-*N*-{2-methyl-4-[(*E*)-4-(1-pyrrolidinyl)-1-butenyl]phenyl}acetamide;

N-[4-(aminosulfonyl)-2-methylphenyl]-2-[4-chloro-2-(3-cyano-5-fluorobenzoyl)phenoxy]acetamide;

N-[4-(aminosulfonyl)-2-methylphenyl]-2-[4-chloro-2-(3-cyano-5-methylbenzoyl)phenoxy]acetamide;

N-[6-(aminosulfonyl)-4-methyl-3-pyridinyl]-2-[4-chloro-2-(3-cyano-5-methylbenzoyl)phenoxy]acetamide;

N-[4-(aminosulfonyl)-2-methylphenyl]-2-[4-chloro-2-(3-chloro-5-cyanobenzoyl)phenoxy]acetamide;

N-[4-(aminosulfonyl)-2-methylphenyl]-2-[4-chloro-2-(3,5-dimethylbenzoyl)phenoxy]acetamide;

N-[4-(aminosulfonyl)-2-methylphenyl]-2-[4-chloro-2-(3-cyano-5-ethylbenzoyl)phenoxy]acetamide;

2-[4-chloro-2-(3-cyano-5-methylbenzoyl)phenoxy]-*N*-{4-[3-(2,5-dihydro-1*H*-pyrrol-1-yl)propoxy]-2-methylphenyl}acetamide hydrochloride;

N-[4-(aminosulfonyl)-2-methylphenyl]-2-[4-chloro-2-(3-chloro-5-methylbenzoyl)phenoxy]acetamide;

N-[4-(aminosulfonyl)-2-methylphenyl]-2-[4-chloro-2-(3,5-dichlorobenzoyl)phenoxy]acetamide;

N-[4-(aminosulfonyl)-2-methylphenyl]-2-{4-chloro-2-[(6-cyano-2-pyridinyl)carbonyl]phenoxy}acetamide;

N-[6-(aminosulfonyl)-2-methyl-3-pyridinyl]-2-[4-chloro-2-(3-cyano-5-methylbenzoyl)phenoxy]acetamide;

N-[4-(aminosulfonyl)-2-methylphenyl]-2-[4-chloro-2-(3,5-dicyanobenzoyl)phenoxy]acetamide;

N-[4-(aminosulfonyl)-2-methylphenyl]-2-{4-chloro-2-[3-cyano-5-(trifluoromethyl)benzoyl]phenoxy}acetamide;

and pharmaceutically acceptable salts thereof.

Serial No. 10/070,084
Docket No. PU3517USw
Reply to Office Action of March 30, 2006

Claim 24 (canceled)

Claim 25 (previously presented) A compound selected from the group consisting of:

N-[4-(aminosulfonyl)-2-methylphenyl]-2-[4-chloro-2-(3-cyanobenzoyl)phenoxy]acetamide;

N-[4-(aminosulfonyl)-2-methylphenyl]-2-[4-chloro-2-(3-fluoro-5-(trifluoromethyl)benzoyl)phenoxy]acetamide;

N-[4-[3-(aminosulfonyl)propoxy]-2-methylphenyl]-2-[4-chloro-2-(3-fluoro-5-(trifluoromethyl)benzoyl)phenoxy]acetamide;

N-[4-(aminosulfonyl)-2-methylphenyl]-2-[4-chloro-2-(3-cyano-5-fluorobenzoyl)phenoxy]acetamide;

N-[4-(aminosulfonyl)-2-methylphenyl]-2-[4-chloro-2-(3-cyano-5-methylbenzoyl)phenoxy]acetamide;

N-[6-(aminosulfonyl)-4-methyl-3-pyridinyl]-2-[4-chloro-2-(3-cyano-5-methylbenzoyl)phenoxy]acetamide;

N-[4-(aminosulfonyl)-2-methylphenyl]-2-[4-chloro-2-(3-chloro-5-cyanobenzoyl)phenoxy]acetamide;

N-[4-(aminosulfonyl)-2-methylphenyl]-2-[4-chloro-2-(3,5-dimethylbenzoyl)phenoxy]acetamide;

N-[4-(aminosulfonyl)-2-methylphenyl]-2-[4-chloro-2-(3-cyano-5-ethylbenzoyl)phenoxy]acetamide;

2-[4-chloro-2-(3-cyano-5-methylbenzoyl)phenoxy]-*N*-[4-[3-(2,5-dihydro-1*H*-pyrrol-1-yl)propoxy]-2-methylphenyl]acetamide hydrochloride;

N-[4-(aminosulfonyl)-2-methylphenyl]-2-[4-chloro-2-(3-chloro-5-methylbenzoyl)phenoxy]acetamide;

N-[4-(aminosulfonyl)-2-methylphenyl]-2-[4-chloro-2-(3,5-dichlorobenzoyl)phenoxy]acetamide;

N-[4-(aminosulfonyl)-2-methylphenyl]-2-[4-chloro-2-[(6-cyano-2-pyridinyl)carbonyl]phenoxy]acetamide;

N-[6-(aminosulfonyl)-2-methyl-3-pyridinyl]-2-[4-chloro-2-(3-cyano-5-methylbenzoyl)phenoxy]acetamide;

N-[4-(aminosulfonyl)-2-methylphenyl]-2-[4-chloro-2-(3,5-dicyanobenzoyl)phenoxy]acetamide;

and pharmaceutically acceptable salts thereof.

Serial No. 10/070,084
Docket No. PU3517USw
Reply to Office Action of March 30, 2006

Claim 26 (previously presented) A compound according to claim 4 wherein R¹ is C₆₋₁₄ aryl substituted in the meta position with halogen and wherein R³ is hydrogen and R⁴ is C₆₋₁₄aryl substituted with C₁₋₈alkyl.

Claim 27 (canceled)

Claim 28 (previously presented) A method of treatment of an HIV infection in a mammal comprising administering to said mammal an anti-HIV effective amount of a compound according to claim 2.

Claim 29 (canceled)

Claim 30 (canceled)

Claim 31 (canceled)

Claim 32 (canceled)

Claim 33 (canceled)

Claim 34 (previously presented) A pharmaceutical composition comprising an effective amount of a compound according to claim 2 together with a pharmaceutically acceptable carrier.

Claim 35 (original) A pharmaceutical composition according to claim 34 in the form of a tablet or capsule.

Claim 36 (original) A pharmaceutical composition according to claim 34 in the form of a liquid.


Claim 37 (canceled)

Claim 38 (canceled)

Claim 39 (canceled)

Serial No. 10/070,084
 Docket No. PU3517USw
 Reply to Office Action of March 30, 2006

Claim 40 (previously presented) A compound of formula (III)



wherein

R^1 is phenyl which is substituted in the *meta* position with one or more substituents selected from the group consisting of halogen, $-CF_3$, C_{1-8} alkyl, C_{1-8} alkylamino, alkoxy, C_{3-6} cycloalkyl C_{2-6} alkenyl, C_{6-14} aryl C_{2-6} alkenyl, $-CN$, $-NO_2$, $-NH_2$, $-SR^6$, $-S(O)_2R^6$, $-S(O)R^7$, $-S(O)_2R^7$, $-C(O)R^7$, C_{2-6} alkenyl which may be optionally substituted with a substituent selected from the group consisting of hydroxy, halogen, aryl, and heterocycle, and C_{2-6} alkynyl which may be optionally substituted with a substituent selected from the group consisting of hydroxy, halogen, aryl, C_{3-6} cycloalkyl, and heterocycle;

R^2 is hydrogen;

R^4 is phenyl substituted in the *ortho* position with a substituent selected from the group consisting of hydroxy, halogen, $-CF_3$, or C_{1-8} alkyl and substituted at the *para* position with a substituent selected from the group consisting of hydroxy, halogen, $-CF_3$, C_{1-8} alkyl, hydroxy C_{1-8} alkyl, $-CN$, $-NO_2$, C_{1-8} alkylamino, heterocycle C_{1-8} alkyl, $-C(O)NH_2$, $-S(O)R^7$, $-S(O)_2R^7$, $-C(O)R^7$, $-NS(O)_2R^7$, $-S(O)_2NR^8R^9$, $-S(O)_2NHR^{11}$, $-SO_2R^{11}$, $-OR^{11}$, $-C(O)R^{11}$, $-C(O)NR^{11}$, $-C(O)OR^{11}$, $-NR^{11}$, $-NC(O)R^{11}$, heterocycle C_{2-6} alkenyl, heterocycle which may be optionally substituted with one or more substituents selected from the group consisting of oxo, C_{1-8} alkyl, and $C(O)OR^{11}$, and C_{1-8} alkyl which may be optionally substituted with one or more substituents selected from the group consisting of $-CN$ and heterocycle, optionally substituted with $-C(O)R^{11}$;

R^5 is a substituent in the *para* position relative to X and is selected from the group consisting of halogen, C_{1-8} alkyl, $-NO_2$, $-NH_2$, C_{1-8} alkylamino, CF_3 , or alkoxy;

R^6 is C_{1-8} alkyl, optionally substituted with one or more substituents selected from the group consisting of hydroxy, halogen, $-CF_3$, aryl, and heterocycle;

R^7 is C_{1-8} alkyl, optionally substituted with one or more substituents selected from the group consisting of hydroxy, halogen, aryl, C_{3-6} cycloalkyl and heterocycle; $-NH_2$; or heterocycle;

Serial No. 10/070,084
Docket No. PU3517/USw
Reply to Office Action of March 30, 2006

R^8 and R^9 are independently selected from the group consisting of hydrogen; C_{3-6} cycloalkyl; C_{1-8} alkyl optionally substituted with one or more substituents selected from the group consisting of oxo, heterocycle, CN and C_{6-14} aryl optionally substituted with alkoxy, C_{1-8} alkylamino, C_{1-8} alkylheterocycle, heterocycle, heterocycle- C_{1-8} alkyl, C_{3-6} cycloalkyl- C_{1-8} alkyl, and C_{3-6} cycloalkyl; or $-C(O)NH_2$;

R^{11} is C_{1-8} alkyl, optionally substituted with one or more substituents selected from the group consisting of hydrogen, C_{1-8} alkyl, $-S(O)_2NR^8R^9$, $-NR^8R^9$, and heterocycle, optionally substituted with one or more substituents selected from the group consisting of oxo and C_{1-8} alkyl; or a pharmaceutically acceptable salt thereof.

Claim 41 (canceled)

Claim 42 (canceled)

Claim 43 (previously presented) A compound according to claim 6 wherein R^1 is C_{6-14} aryl substituted in the meta position with halogen and wherein R^3 is hydrogen and R^4 is C_{6-14} aryl substituted with C_{1-8} alkyl.

Claim 44 (previously presented) A compound according to claim 7 wherein R^1 is C_{6-14} aryl substituted in the meta position with halogen and wherein R^3 is hydrogen and R^4 is C_{6-14} aryl substituted with C_{1-8} alkyl.

Claim 45 (previously presented) A compound according to claim 2 wherein R^1 is C_{6-14} aryl substituted in the meta position with halogen and wherein R^3 is hydrogen and R^4 is C_{6-14} aryl substituted with C_{1-8} alkyl.

Claim 46 (previously presented) A compound according to claim 18 wherein R^1 is C_{6-14} aryl substituted in the meta position with halogen and wherein R^3 is hydrogen and R^4 is C_{6-14} aryl substituted with C_{1-8} alkyl.

Claim 47 (previously presented) A compound according to claim 19 wherein R^1 is C_{6-14} aryl substituted in the meta position with halogen and wherein R^3 is hydrogen and R^4 is C_{6-14} aryl substituted with C_{1-8} alkyl.

Serial No. 10/070,084
Docket No. PU3517USw
Reply to Office Action of March 30, 2006

Claim 48 (previously presented) A method of treatment of an HIV infection in a mammal comprising administering to said mammal an effective amount of a compound according to claim 4.

Claim 49 (previously presented) A method of treatment of an HIV infection in a mammal comprising administering to said mammal an effective amount of a compound according to claim 23.

Claim 50 (canceled)

Claim 51 (canceled)

Claim 52 (canceled)

Claim 53 (canceled)

Claim 54 (previously presented) A pharmaceutical composition comprising an effective amount of a compound according to claim 4 together with a pharmaceutically acceptable carrier.

Claim 55 (previously presented) A pharmaceutical composition comprising an effective amount of a compound according to claim 23 together with a pharmaceutically acceptable carrier.

Claim 56 (previously presented) A compound according to claim 7 wherein R⁴ is C₆₋₁₄aryl substituted with methyl.

Claim 57 (canceled)

Claim 58 (previously presented) A compound of formula (I) according to claim 20 wherein R¹ is phenyl which is substituted in the meta position with one or more substituents selected from the group consisting of halogen, -CF₃, C₁₋₈alkyl, and -CN; R⁴ is phenyl substituted with one or more substituents selected from the group consisting of halogen, C₁₋₈alkyl, -CN, -NO₂, -S(O)R⁷, -S(O)₂R⁷, -NS(O)₂R⁷, wherein R⁷ is -NH₂; and R⁵ is halogen; or a pharmaceutically acceptable salt thereof.

Serial No. 10/070,084
Docket No. PU3517USw
Reply to Office Action of March 30, 2006

Claim 59 (previously presented) A compound of formula (I) according to claim 20 wherein R^1 is phenyl which is substituted in the meta position with one or more substituents selected from the group consisting of halogen, C_{1-8} alkyl, CF_3 , $-CN$; R^4 is phenyl substituted with one or more substituents selected from the group consisting of C_{1-8} alkyl and $S(O)_2NR^8R^9$, wherein R^8 and R^9 are independently selected from the group consisting of hydrogen, C_{3-6} cycloalkyl, C_{1-8} alkyl optionally substituted with one or more substituents selected from the group consisting of oxo, heterocycle, CN and C_{6-14} aryl optionally substituted with C_{1-8} alkoxy, C_{1-8} alkylamino, C_{1-8} alkylheterocycle, heterocycle, heterocycle C_{1-8} alkyl, C_{3-6} cycloalkyl C_{1-8} alkyl, and C_{3-6} cycloalkyl.

Claim 60 (previously presented) A compound of formula (I) according to claim 20 wherein R^1 is phenyl which is substituted in the meta position with one or more substituents selected from the group consisting of halogen, $-CF_3$, C_{1-8} alkyl, $-CN$, C_{2-6} alkenyl which may be optionally substituted with a substituent selected from the group consisting of hydroxy, halogen, aryl, and heterocycle and C_{2-6} alkynyl which may be optionally substituted with a substituent selected from the group consisting of hydroxy, halogen, aryl, C_{3-6} cycloalkyl, and heterocycle; R^4 is phenyl substituted with one or more substituents selected from the group consisting of C_{1-8} alkyl, $-S(O)_2R^7$, $-S(O)_2NR^8R^9$, $-OR^{11}$, heterocycle C_{2-6} alkenyl, and heterocycle which may be optionally substituted with oxo; and R^5 is halogen; or a pharmaceutically acceptable salt thereof.

Claim 61 (previously presented) A compound of formula (III) according to claim 40 wherein R^1 is phenyl which is substituted in the meta position with one or more substituents selected from the group consisting of halogen, $-CF_3$, C_{1-8} alkyl, $-CN$, $-SR^6$, $-S(O)_2R^6$; R^6 is C_{1-8} alkyl, optionally substituted with halogen; R^7 is C_{1-8} alkyl, optionally substituted with hydroxy; $-NH_2$; or heterocycle; R^4 is phenyl substituted with one or more substituents selected from the group consisting of hydroxy, $-CF_3$, C_{1-8} alkyl, hydroxy C_{1-8} alkyl, $-CN$, $-NO_2$, $-C(O)NH_2$, $-S(O)_2R^7$, $-S(O)_2NR^8R^9$, $-OR^{11}$, $-C(O)NR^{11}$, $-C(O)OR^{11}$, $-NR^{11}$, $-NC(O)R^{11}$, heterocycle which may be optionally substituted with one or more substituents selected from the group consisting of oxo and C_{1-8} alkyl; R^8 and R^9 are the same or different and are selected from the group consisting of hydrogen, C_{1-8} alkyl, C_{1-8} alkylheterocycle, heterocycle, and C_{3-6} cycloalkyl; R^{10} is C_{1-8} alkyl; R^{11} is C_{1-8} alkyl, optionally substituted with $-S(O)_2NR^8R^9$; and R^5 is halogen or $-NO_2$, or a pharmaceutically acceptable salt thereof.

Claim 62 (previously presented) A compound of formula (I) according to claim 60 wherein R^1 is phenyl which is substituted in the meta position with one or more substituents selected from the group consisting of halogen, $-CF_3$, C_{1-8} alkyl, and $-CN$; R^4 is phenyl substituted with one or more substituents selected from the group consisting of halogen, C_{1-8} alkyl, $-CN$, $-NO_2$,

Serial No. 10/070,084
Docket No. PU3517USw
Reply to Office Action of March 30, 2006

-S(O)R⁷, -S(O)₂R⁷, -NS(O)₂R⁷, wherein R⁷ is -NH₂; and R⁵ is halogen; or a pharmaceutically acceptable salt thereof.

Claim 63 (new) A method of treatment of an HIV infection in a mammal comprising administering to said mammal an effective amount of a compound according to claim 6.

Claim 64 (new) A method of treatment of an HIV infection in a mammal comprising administering to said mammal an effective amount of a compound according to claim 10.

Claim 65 (new) A method of treatment of an HIV infection in a mammal comprising administering to said mammal an effective amount of a compound according to claim 18.

Claim 66 (new) A method of treatment of an HIV infection in a mammal comprising administering to said mammal an effective amount of a compound according to claim 4.

Claim 67 (new) A pharmaceutical composition comprising an effective amount of a compound according to claim 6 together with a pharmaceutically acceptable carrier.

Claim 68 (new) A pharmaceutical composition according to claim 67 in the form of a tablet or capsule.

Claim 69 (new) A pharmaceutical composition according to claim 67 in the form of a liquid.

Claim 70 (new) A pharmaceutical composition comprising an effective amount of a compound according to claim 10 together with a pharmaceutically acceptable carrier.

Claim 71 (new) A pharmaceutical composition comprising an effective amount of a compound according to claim 18 together with a pharmaceutically acceptable carrier.

Claim 72 (new) A pharmaceutical composition comprising an effective amount of a compound according to claim 4 together with a pharmaceutically acceptable carrier.